Do monoclonal antibodies and anticytokines still have a future in infectious diseases?

The American Journal of Medicine
J CohenM P Glauser

Abstract

The continuing high mortality of septic shock has prompted a major effort by the research community to identify novel therapeutic targets. These targets can be conveniently grouped into (1) those derived from microbial components or products; (2) inflammatory mediators; and (3) effector molecules. Many of the experimental, so-called adjunctive agents developed have been monoclonal antibodies or anticytokine molecules of various kinds, and some have progressed into clinical trial. Unfortunately, these trials have failed to show unequivocal survival benefit for patients in shock, prompting a reappraisal of our approach to these agents. In this article, we discuss the possible reasons for these failures: (1) the targets are wrong; (2) the agents are inappropriate; or (3) the trial design is flawed. It would be premature to conclude that adjunctive agents have no future in the therapy of sepsis, but identifying the correct agent, and perhaps more importantly, the correct target population, is going to be more difficult than was at first believed.

References

Nov 1, 1992·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·J C Hurley
Jul 1, 1992·Archives of Internal Medicine·R C Bone
Jan 1, 1990·Critical Reviews in Microbiology·G A BohachP M Schlievert
May 1, 1990·Proceedings of the National Academy of Sciences of the United States of America·R G KilbournR F Lodato
Dec 30, 1993·The New England Journal of Medicine·S Moncada, A Higgs
Feb 1, 1994·The Journal of Infectious Diseases·T EvansJ Cohen
Jul 7, 1995·Annals of the New York Academy of Sciences·B Gulwani-AkolkarJ Silver
Jan 1, 1995·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·W A Lynn, J Cohen
Apr 29, 1994·Science·B Beutler, C van Huffel
Jan 14, 1993·The New England Journal of Medicine·C A Dinarello, S M Wolff
Apr 1, 1993·The Journal of Experimental Medicine·M HowardS Menon
May 1, 1993·The Journal of Infectious Diseases·P M Schlievert

❮ Previous
Next ❯

Citations

Nov 14, 1997·Nature Medicine·G E Grau, D N Maennel
Nov 18, 1997·Human & Experimental Toxicology·C BismuthJ M Scherrmann
Jun 2, 2004·Cytometry. Part a : the Journal of the International Society for Analytical Cytology·Henning UlrichJoão Bosco Pesquero

❮ Previous
Next ❯

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

Blastomycosis

Blastomycosis fungal infections spread through inhaling Blastomyces dermatitidis spores. Discover the latest research on blastomycosis fungal infections here.

Nuclear Pore Complex in ALS/FTD

Alterations in nucleocytoplasmic transport, controlled by the nuclear pore complex, may be involved in the pathomechanism underlying multiple neurodegenerative diseases including Amyotrophic Lateral Sclerosis and Frontotemporal Dementia. Here is the latest research on the nuclear pore complex in ALS and FTD.

Applications of Molecular Barcoding

The concept of molecular barcoding is that each original DNA or RNA molecule is attached to a unique sequence barcode. Sequence reads having different barcodes represent different original molecules, while sequence reads having the same barcode are results of PCR duplication from one original molecule. Discover the latest research on molecular barcoding here.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Evolution of Pluripotency

Pluripotency refers to the ability of a cell to develop into three primary germ cell layers of the embryo. This feed focuses on the mechanisms that underlie the evolution of pluripotency. Here is the latest research.

Position Effect Variegation

Position Effect Variagation occurs when a gene is inactivated due to its positioning near heterochromatic regions within a chromosome. Discover the latest research on Position Effect Variagation here.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Microbicide

Microbicides are products that can be applied to vaginal or rectal mucosal surfaces with the goal of preventing, or at least significantly reducing, the transmission of sexually transmitted infections. Here is the latest research on microbicides.